Infinimmune, a biotechnology company pioneering antibody discovery and design, entered a collaboration with Merck to apply Infinimmune’s human-first antibody discovery platform to identify and develop antibody candidates against multiple undisclosed targets designated by Merck. Infinimmune will use its Anthrobody discovery platform and GLIMPSE antibody language model to discover and optimize therapeutic antibodies derived directly from human immune repertoires. The Infinimmune platform enable...